20 August 2026
A Moderna-Merck melanoma vaccine reduces recurrence and spread in a late-stage trial, boosting hopes for mRNA cancer treatments.
16 March 2026
Cape Town biotech firm Afrigen’s business rescue begins as the WHO-backed mRNA hub seeks new investment to secure vaccine manufacturing.